非オピオイド性疼痛治療の市場規模、シェア、動向分析レポート：薬剤クラス別、疼痛別、投与経路別、流通経路別、地域別、セグメント予測、2025年～2030年

非オピオイド性疼痛治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の非オピオイド性疼痛治療市場規模は2030年までに703億米ドルに達し、2025～2030年のCAGRは7.69％を記録すると予測されています。

この成長は、新規非オピオイド鎮痛薬の強固な製品パイプラインと相まって、炎症性疾患の有病率の増加に起因しています。米国疾病予防管理センター（CDC）によると、米国では約3,250万人が変形性関節症を患っており、米国脊椎炎協会によると、米国では約320万人が何らかの形で脊椎関節症を患っています。

政府や非営利団体は、痛みを和らげる医薬品の需要増に対応するため、NSAIDsのようなオピオイドに代わるより安全な医薬品の使用を促進する取り組みを行っています。例えば、米国FDAは2022年2月、30日間持続する急性疼痛の治療としてNSAIDsを開発するよう製薬会社に勧告するガイドライン案を発表しました。このイニシアチブは、オピオイド過剰摂取患者の予防、減少、治療、回復に焦点を当てた政府の「HHS過剰摂取防止戦略」の一環です。このような取り組みにより、予測期間中、NSAID医薬品の需要が促進されると予測されます。

市場の主要参入企業は、疼痛管理のためのNSAIDsの需要増に対応するため、革新的な技術を積極的に開発しています。例えば、2021年6月、アリゾナ大学は、苦しむ患者の治療のためにオキシトシンアナログを開発しました。これは生物学的に利用可能な非オピオイド鎮痛剤で、吸入投与が可能です。このような革新的な製品の開発は、非オピオイド鎮痛剤治療市場の成長を促進すると予想されます。

2022年9月、米国FDAは、胎児に腎障害が起こる可能性が高いとして、妊娠20週での非オピオイド鎮痛薬治療の回避を推奨しました。このような各国政府の取り組みにより、NSAIDsの配合が制限される可能性があり、非オピオイド鎮痛薬市場の成長が抑制される可能性があります。

企業は非オピオイド鎮痛薬の浸透を高めるため、新製品開発、上市、提携などの戦略を採用しています。例えば、バーテックス・ファーマシューティカルズは2022年3月、第2相臨床検査で非オピオイド錠剤が術後の急性疼痛を有意に軽減するという良好な結果を発表しました。治験の成功とその後の製品の承認が、予測期間中の非オピオイド鎮痛薬治療市場の成長を促進すると予想されます。

同市場は競争が激しく、多数の参入企業が存在するため、予測期間中の市場競争は高水準になると予想されます。ジェネリックNSAID製品を製造している主要企業には、GSK plc.、Sun Pharmaceutical Industries Ltd.、Novartis AG、Teva Pharmaceutical Industries Ltd.、Viatris Inc.、Johnson & Johnson Services, Inc.などがあります。

非オピオイド性疼痛治療市場のレポートハイライト

• 2024年には、NSAIDsセグメントが最大の市場シェアを占め、疼痛治療に対する高い需要と近年の複数のNSAIDsの商業化により、予測期間中もその優位性を維持すると予測されます。
• 2024年には慢性疼痛が最も高いシェアを占める。製品承認の増加、慢性疼痛の罹患率の高さ、革新的な非ステロイド性抗炎症薬製品を発売するための研究開発イニシアチブの高さなどの要因が、この優位性につながっています。
• 投与経路タイプ別では、経口のNSAIDs製品は投与が容易であり、市場で広く入手可能であることから、経口投与セグメントが2024年に最も高いシェアを占めました。
• 流通チャネル別では、小売薬局が2024年に54.39%のシェアを占め、市場を独占すると予想されます。この優位性は、多数のジェネリック非ステロイド性抗炎症薬が存在することと、小売薬局のネットワークが充実しているため患者が容易に入手できることに起因しています。
• アジア太平洋は、NSAIDs製品の普及率の上昇、可処分所得の増加、新興諸国における炎症性疾患の有病率の高さなどから、予測期間中に最も速い成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 非オピオイド鎮痛治療市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 非オピオイド鎮痛治療市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
• 価格分析

第4章 非オピオイド鎮痛治療市場：薬剤クラス別、推定・動向分析

• セグメントダッシュボード
• 世界の非オピオイド鎮痛治療市場：薬剤クラスの変動分析
• 薬剤別、クラス別収益
• NSAID
  • 非選択的NSAID
  • 選択的COX-2阻害剤
• アセトアミノフェン
• 局所麻酔薬
• その他

第5章 非オピオイド鎮痛治療市場： 疼痛別、推定・動向分析

• セグメントダッシュボード
• 世界の非オピオイド鎮痛治療市場：疼痛の変動分析
• 痛み、収益
• 術後の痛み
• がんの痛み
• 慢性疼痛
• その他の痛み

第6章 非オピオイド鎮痛治療市場：投与経路別、推定・動向分析

• セグメントダッシュボード
• 世界の非オピオイド鎮痛治療市場：投与経路の変動分析
• 投与経路別収益
• 経口
• 局所
• 注射
• その他

第7章 非オピオイド鎮痛治療市場：流通チャネル別、推定・動向分析

• セグメントダッシュボード
• 世界の非オピオイド鎮痛治療市場：流通チャネルの変動分析
• 流通チャネル別、収益
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 非オピオイド鎮痛治療市場： 薬剤クラス、鎮痛、投与経路、流通チャネルによる地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2024年
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Sun Pharmaceutical Industries Ltd
  • GSK plc.
  • Pfizer Inc.
  • Perrigo Company plc.
  • LNK International, Inc.
  • Cipla Inc.
  • Johnson & Johnson Services, Inc.
  • Pacira Pharmaceuticals, Inc.
  • Pierrel

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviations
• Table 3 List of key distributors
• Table 4 List of other companies
• Table 5 List of key emerging company's/technology disruptors/innovators
• Table 6 North America Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 8 North America Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 9 North America Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 11 U.S. Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 12 U.S. Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 13 U.S. Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 14 U.S. Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 16 Canada Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 17 Canada Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Canada Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Mexico Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 20 Mexico Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 21 Mexico Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 22 Mexico Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 Europe Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 24 Europe Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 25 Europe Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 26 Europe Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 27 Europe Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 UK Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 29 UK Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 30 UK Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 UK Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Germany Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 33 Germany Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 34 Germany Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 35 Germany Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 36 France Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 37 France Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 38 France Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 France Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Spain Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 41 Spain Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 42 Spain Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Spain Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Italy Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 45 Italy Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 46 Italy Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 47 Italy Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Denmark Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 49 Denmark Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 50 Denmark Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Denmark Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Sweden Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 53 Sweden Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 54 Sweden Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 55 Sweden Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Norway Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 57 Norway Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 58 Norway Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 59 Norway Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 64 Japan Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 65 Japan Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 66 Japan Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 67 Japan Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 China Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 69 China Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 70 China Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 71 China Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 India Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 73 India Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 74 India Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 75 India Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Australia Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 77 Australia Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 78 Australia Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 79 Australia Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 80 South Korea Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 81 South Korea Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 82 South Korea Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 83 South Korea Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 Thailand Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 85 Thailand Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 86 Thailand Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 Thailand Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 Latin America Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 89 Latin America Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 90 Latin America Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 91 Latin America Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 92 Latin America Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 93 Brazil Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 94 Brazil Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 95 Brazil Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 96 Brazil Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 97 Argentina Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 98 Argentina Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 99 Argentina Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 100 Argentina Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 101 MEA Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 102 MEA Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 103 MEA Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 104 MEA Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 105 MEA Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 106 South Africa Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 107 South Africa Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 108 South Africa Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 109 South Africa Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 114 UAE Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 115 UAE Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 116 UAE Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 117 UAE Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 118 Kuwait Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
• Table 119 Kuwait Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
• Table 120 Kuwait Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 121 Kuwait Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Non-opioid pain treatment market Segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Non- opioid pain treatment market snapshot
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Non- opioid pain treatment market driver impact
• Fig. 14 Non- opioid pain treatment market restraint impact
• Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 16 Industry Analysis - Porter's Five Forces
• Fig. 17 Strategy mapping
• Fig. 18 Non-opioid pain treatment market: Drug class outlook and key takeaways
• Fig. 19 Non- opioid pain treatment market: Drug class movement analysis & market share 2024 & 2030
• Fig. 20 NSAIDs non-opioid treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Non-selective NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Selective COX-2 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Acetaminophen market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Local Anesthetics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Other drug class market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Non-opioid treatment market: Pain outlook and key takeaways
• Fig. 27 Non-opioid treatment market: Pain movement analysis & market share 2024 & 2030
• Fig. 28 Post-operative pain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Cancer pain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Other pain non-opioid treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Non- non-opioid treatment market: Distribution channel outlook and key takeaways
• Fig. 33 Non- non-opioid treatment market: Distribution channel movement analysis & market share 2024 & 2030
• Fig. 34 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Global Non-opioid Pain Treatment market: Regional movement analysis
• Fig. 38 Global Non-opioid Pain Treatment market: Regional outlook and key takeaways
• Fig. 39 Global Non-opioid Pain Treatment market share and leading players
• Fig. 40 North America, by country
• Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 U.S. key country dynamics
• Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Canada key country dynamics
• Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Mexico key country dynamics
• Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UK key country dynamics
• Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Germany key country dynamics
• Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 France key country dynamics
• Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Italy key country dynamics
• Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Spain key country dynamics
• Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Denmark key country dynamics
• Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Sweden key country dynamics
• Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Norway key country dynamics
• Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China key country dynamics
• Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Japan key country dynamics
• Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 India key country dynamics
• Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Thailand key country dynamics
• Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 South Korea key country dynamics
• Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Australia key country dynamics
• Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Brazil key country dynamics
• Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Argentina key country dynamics
• Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 South Africa key country dynamics
• Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Saudi Arabia key country dynamics
• Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 UAE key country dynamics
• Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Kuwait key country dynamics
• Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Market share Analysis of key market players, 2024

Non-opioid Pain Treatment Market Growth & Trends:

The global non-opioid pain treatment market size is expected to reach USD 70.30 billion by 2030, registering a CAGR of 7.69% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government's "HHS Overdose Prevention Strategy" which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.

Non-opioid Pain Treatment Market Report Highlights:

• In 2024, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years
• Chronic pain was the accounted for highest share in 2024. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
• Based on route of administration type, the oral segment accounted for the highest share in 2024 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
• Based on the distribution channel, retail pharmacies are expected to dominate the market with a 54.39% share in 2024. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
• Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Pain
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class and pain outlook
  • 2.2.2. Route of administration and distribution channel outlook
• 2.3. Competitive Insights

Chapter 3. Non-opioid Pain Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High prevalence of chronic & inflammatory diseases globally
    • 3.2.1.2. Increasing product approvals and launches
    • 3.2.1.3. Supportive regulatory and reimbursement policies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations
    • 3.2.2.2. Side-effects associated with drug
• 3.3. Non-opioid Pain Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis

Chapter 4. Non-opioid Pain Treatment Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Non-opioid Pain Treatment Market: Drug Class Movement Analysis
• 4.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Drug, Class Revenue (USD Million)
• 4.4. NSAIDs
  • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Non-Selective NSAIDs
    • 4.4.2.1. Non-Selective NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Selective COX-2 Inhibitors
    • 4.4.3.1. Selective COX-2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Acetaminophen
  • 4.5.1. Acetaminophen market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Local Anesthetics
  • 4.6.1. Local Anesthetics market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Drug Class
  • 4.7.1. Others drug class market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-opioid Pain Treatment Market: Pain Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Non-opioid Pain Treatment Market: Pain Movement Analysis
• 5.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Pain, Revenue (USD Million)
• 5.4. Post-operative Pain
  • 5.4.1. Post-operative pain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cancer Pain
  • 5.5.1. Cancer pain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Chronic Pain
  • 5.6.1. Chronic pain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Other Pain
  • 5.7.1. Other pain market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-opioid Pain Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Non-opioid Pain Treatment Market: Route of Administration Movement Analysis
• 6.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 6.4. Oral
  • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Topical
  • 6.5.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Injectable
  • 6.6.1. Injectable market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Other Route of Administration
  • 6.7.1. Other route of administration market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Non-opioid Pain Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Non-opioid Pain Treatment Market: Distribution Channel Movement Analysis
• 7.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 7.4. Hospitals Pharmacies
  • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Non-opioid Pain Treatment Market: Regional Estimates & Trend Analysis By Drug Clas, Pain, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Novartis AG
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Teva Pharmaceutical Industries Limited
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Teva Pharmaceutical Industries Limited
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Sun Pharmaceutical Industries Ltd
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. GSK plc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Pfizer Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Perrigo Company plc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. LNK International, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Cipla Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Johnson & Johnson Services, Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Pacira Pharmaceuticals, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Pierrel
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives